| First Author | Welch SR | Year | 2023 |
| Journal | Sci Adv | Volume | 9 |
| Issue | 31 | Pages | eadh4057 |
| PubMed ID | 37540755 | Mgi Jnum | J:348458 |
| Mgi Id | MGI:7517719 | Doi | 10.1126/sciadv.adh4057 |
| Citation | Welch SR, et al. (2023) Single-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination. Sci Adv 9(31):eadh4057 |
| abstractText | Nipah virus (NiV) causes a highly lethal disease in humans who present with acute respiratory or neurological signs. No vaccines against NiV have been approved to date. Here, we report on the clinical impact of a novel NiV-derived nonspreading replicon particle lacking the fusion (F) protein gene (NiVDeltaF) as a vaccine in three small animal models of disease. A broad antibody response was detected that included immunoglobulin G (IgG) and IgA subtypes with demonstrable Fc-mediated effector function targeting multiple viral antigens. Single-dose intranasal vaccination up to 3 days before challenge prevented clinical signs and reduced virus levels in hamsters and immunocompromised mice; decreases were seen in tissues and mucosal secretions, critically decreasing potential for virus transmission. This virus replicon particle system provides a vital tool to the field and demonstrates utility as a highly efficacious and safe vaccine candidate that can be administered parenterally or mucosally to protect against lethal Nipah disease. |
